Your browser doesn't support javascript.
loading
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts, Alison; Clark, Tracey; Jasper, Paul; Tolsma, John; van der Graaf, Piet H; Graziani, Edmund I; Rosfjord, Edward; Sung, Matthew; Ma, Dangshe; Barletta, Frank.
Afiliação
  • Betts A; Department of Biomedicine Design, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA. alison.betts@appliedbiomath.com.
  • Clark T; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, 2300 RA, Leiden, The Netherlands. alison.betts@appliedbiomath.com.
  • Jasper P; Applied Biomath, 561 Virginia Rd, Suite 220, Concord, MA, 01742, USA. alison.betts@appliedbiomath.com.
  • Tolsma J; Worldwide Research Procurement, Pfizer Inc, Eastern Point Rd, Groton, CT, 06340, USA.
  • van der Graaf PH; RES Group, Inc, 75 Second Avenue, Needham, MA, 02494, USA.
  • Graziani EI; RES Group, Inc, 75 Second Avenue, Needham, MA, 02494, USA.
  • Rosfjord E; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, 2300 RA, Leiden, The Netherlands.
  • Sung M; Apertor Labs Inc, 828 Contra Costa Ave, Berkeley, CA, 94707, USA.
  • Ma D; Oncology Research & Development, Pfizer Inc, 401 N Middletown Rd, Pearl River, NY, 10965, USA.
  • Barletta F; Oncology Research & Development, Pfizer Inc, 401 N Middletown Rd, Pearl River, NY, 10965, USA.
J Pharmacokinet Pharmacodyn ; 47(5): 513-526, 2020 10.
Article em En | MEDLINE | ID: mdl-32710210

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Imunoconjugados / Antineoplásicos Imunológicos / Ado-Trastuzumab Emtansina / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Imunoconjugados / Antineoplásicos Imunológicos / Ado-Trastuzumab Emtansina / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos